MedTrace Logo

A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure

NCT01913301 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2013-08-01

No results posted yet for this study

Summary

The purpose of the study is to gather information regarding the safety and effectiveness of an investigational drug called Alagebrium when used treating Heart Failure in relation to exercise tolerance after 6 months in the trial.

Conditions

  • Diastolic Heart Failure

Interventions

DRUG

Alagebrium

Sponsors & Collaborators

  • Cardiovascular Clinical Sciences Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-05-31
Completion
2009-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01913301 on ClinicalTrials.gov